Axa
AEGR

Axa’s Aegerion Pharmaceuticals AEGR Stock Holding History

Axa’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-142,823
Closed -$4.58M – 1513
2014
Q2 		$4.58M Sell
142,823
-8,333
-6% -$310K 0.02% 567
2014
Q1 		$6.97M Sell
151,156
-47,973
-24% -$2.81M 0.03% 461
2013
Q4 		$14.1M Buy
199,129
+130,839
+192% +$10M 0.06% 307
2013
Q3 		$5.85M Buy
68,290
+4,263
+7% +$361K 0.03% 485
2013
Q2 		$4.05M Buy
+64,027
New +$3.4M 0.02% 522

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's AEGR Position: Q3 2014 in Review

Axa sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 142,823 shares — an estimated $4.58M sold.

Axa first reported a position in AEGR in Q2 2013 and held it in 5 quarters. The position peaked at $14.1M in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • Axa reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Axa sold 142,823 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $4.58M.
  • Axa first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Axa's Aegerion Pharmaceuticals position peaked at $14.1M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Axa's 13F filing for Q3 2014, filed 13 Nov 2014.